Loring Wolcott & Coolidge Fiduciary Advisors LLP Vertex Pharmaceuticals Inc Transaction History
Loring Wolcott & Coolidge Fiduciary Advisors LLP
- $10.5 Billion
- Q2 2024
A detailed history of Loring Wolcott & Coolidge Fiduciary Advisors LLP transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Loring Wolcott & Coolidge Fiduciary Advisors LLP holds 559 shares of VRTX stock, worth $261,785. This represents 0.0% of its overall portfolio holdings.
Number of Shares
559
Previous 559
-0.0%
Holding current value
$261,785
Previous $233,000
12.45%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding VRTX
# of Institutions
1,707Shares Held
226MCall Options Held
1.2MPut Options Held
1.59M-
Capital World Investors Los Angeles, CA26.7MShares$12.5 Billion2.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA23MShares$10.8 Billion0.21% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$9.98 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.7MShares$5.49 Billion0.24% of portfolio
-
Capital Research Global Investors Los Angeles, CA8.54MShares$4 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $120B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...